Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Earth Science TechETST -4.00%36 EV-to-EBIT is 10.48 as of Jul. 26, 2026. GuruFocus rates ETST with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Earth Science Tech ranks better than 69.13% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Earth Science Tech's Enterprise Value for the quarter that ended in Mar. 2026 was $23.87 Mil.
Earth Science Tech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Earth Science Tech EV-to-EBIT Related Terms
Earth Science Tech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Earth Science Tech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Earth Science Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earth Science Tech EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Earth Science Tech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Earth Science Tech's EV-to-EBIT falls into.
Earth Science Tech's current Enterprise Value is $32.55 Mil.
Earth Science Tech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Earth Science Tech (ETST) has a EV-to-EBIT of 10.48 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Earth Science Tech and its competitors. According to the industry distribution chart, Earth Science Tech ranks #213 out of 690 companies in the Drug Manufacturers industry, placing it in the top 30.9%.
Is Earth Science Tech's EV-to-EBIT too high?
Earth Science Tech's current EV-to-EBIT is 10.48. The Drug Manufacturers industry median EV-to-EBIT is 15.42. Earth Science Tech's value of 10.48 is 32% below this industry median. Based on the distribution chart, Earth Science Tech ranks #213 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Earth Science Tech has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Earth Science Tech's EV-to-EBIT compare to IXHL and BTAI?
According to the Drug Manufacturers industry distribution chart, Earth Science Tech ranks #213 out of 690 companies for EV-to-EBIT. This puts Earth Science Tech in the upper half of its industry. The industry median EV-to-EBIT is 15.42. Earth Science Tech's value of 10.48 is 32% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earth Science Tech's current EV-to-EBIT of 10.48 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Earth Science Tech and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earth Science Tech's current EV-to-EBIT is 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earth Science Tech stock overvalued right now?
Earth Science Tech (ETST) has a current EV-to-EBIT of 10.48. The current EV-to-EBIT is 10.48 and 32% below the Drug Manufacturers industry median of 15.42. Earth Science Tech's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Earth Science Tech (ETST), the current EV-to-EBIT is 10.48 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Earth Science Tech Inc is a diversified holding company. The company focuses on the health and wellness sector. The Company's principal operating plan is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment.
36GF Score
Get the complete analysis for ETST
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETST has been successfully added to your 
